Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481397 · ClinicalTrials.gov registry record · NA
OSCAR I STUDY - The ONCObind CTC Removal Study
A NA study, sponsored by ExThera Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT06481397: Completed NA study, sponsored by ExThera Medical Corporation.
NCT06481397 is a NA study that has completed, run by ExThera Medical Corporation. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06481397, a NA study, has completed, sponsored by ExThera Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic therapy. Site selection will be dependent upon the site's familiarity with extracorporeal blood purification platforms as well as the diagnosis and management of PDAC. Adults (18 years old and older, ECOG PS of equal or less than 2) with a diagnosis of PDAC as defined histologically (microscopically) as a "pancreatobiliary type" adenocarcinoma with at least 5 U/mL CTCs in peripheral blood and/or portal vein.
Primary Outcome
Incidence of treatment-emergent adverse events (AEs), graded using the NCI CTCAE Version 5.0.
Interventions
- DEVICE ONCObind (Onco-Seraph) 100 Filter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-08-29 |
| Est. Completion | 2024-10-18 |
| Phase | NA |
What the finished NCT06481397 record still lists
NCT06481397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which ONCObind (Onco-Seraph) 100 Filter is the first listed.
NCT06481397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06481397 about?
NCT06481397 is a clinical study titled "OSCAR I STUDY - The ONCObind CTC Removal Study". This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic therapy. Site selection will be dependent upon the site's familiarity with ...
What is the current status of trial NCT06481397?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2024-08-29. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT06481397?
The interventions under investigation include: ONCObind (Onco-Seraph) 100 Filter (DEVICE).
Who is sponsoring clinical trial NCT06481397?
This trial is sponsored by ExThera Medical Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06481397's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI